nodes	percent_of_prediction	percent_of_DWPC	metapath
Remifentanil—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00554	0.029	CbGpPWpGaD
Remifentanil—OPRM1—nerve—acquired immunodeficiency syndrome	0.00496	0.255	CbGeAlD
Remifentanil—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00486	0.0254	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0043	0.0225	CbGpPWpGaD
Remifentanil—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00411	0.0215	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00377	0.0197	CbGpPWpGaD
Remifentanil—Alfentanil—ALB—acquired immunodeficiency syndrome	0.00348	0.689	CrCbGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00319	0.0167	CbGpPWpGaD
Remifentanil—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0031	0.0162	CbGpPWpGaD
Remifentanil—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00291	0.0152	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00289	0.0151	CbGpPWpGaD
Remifentanil—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00272	0.0142	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00261	0.0136	CbGpPWpGaD
Remifentanil—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00255	0.0133	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00253	0.0132	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00236	0.0123	CbGpPWpGaD
Remifentanil—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0023	0.012	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00229	0.012	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0022	0.0115	CbGpPWpGaD
Remifentanil—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00216	0.0113	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00214	0.0112	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00207	0.0108	CbGpPWpGaD
Remifentanil—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.002	0.0104	CbGpPWpGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00193	0.0101	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00193	0.0101	CbGpPWpGaD
Remifentanil—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.00188	0.00985	CbGpPWpGaD
Remifentanil—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.00188	0.00985	CbGpPWpGaD
Remifentanil—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.00183	0.00958	CbGpPWpGaD
Remifentanil—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00175	0.00915	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00175	0.00914	CbGpPWpGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00175	0.00913	CbGpPWpGaD
Remifentanil—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00164	0.0841	CbGeAlD
Remifentanil—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00163	0.00852	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00161	0.00842	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00158	0.00827	CbGpPWpGaD
Remifentanil—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00158	0.081	CbGeAlD
Remifentanil—Pethidine—ALB—acquired immunodeficiency syndrome	0.00157	0.311	CrCbGaD
Remifentanil—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00157	0.0807	CbGeAlD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00153	0.00802	CbGpPWpGaD
Remifentanil—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00151	0.0777	CbGeAlD
Remifentanil—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00148	0.00773	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00146	0.00761	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00141	0.00738	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00139	0.00725	CbGpPWpGaD
Remifentanil—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.00138	0.00723	CbGpPWpGaD
Remifentanil—OPRM1—blood—acquired immunodeficiency syndrome	0.00138	0.0707	CbGeAlD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00137	0.00716	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00137	0.00716	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00133	0.00696	CbGpPWpGaD
Remifentanil—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00132	0.0681	CbGeAlD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0013	0.00678	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00128	0.00668	CbGpPWpGaD
Remifentanil—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.00126	0.00661	CbGpPWpGaD
Remifentanil—OPRD1—brain—acquired immunodeficiency syndrome	0.00125	0.0643	CbGeAlD
Remifentanil—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00123	0.00642	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.0012	0.0063	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.0012	0.00628	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.0012	0.00628	CbGpPWpGaD
Remifentanil—OPRK1—brain—acquired immunodeficiency syndrome	0.0012	0.0617	CbGeAlD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00119	0.00624	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00117	0.00613	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00117	0.0061	CbGpPWpGaD
Remifentanil—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00116	0.00604	CbGpPWpGaD
Remifentanil—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00116	0.00604	CbGpPWpGaD
Remifentanil—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00114	0.00596	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00113	0.0059	CbGpPWpGaD
Remifentanil—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00112	0.0574	CbGeAlD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00108	0.00565	CbGpPWpGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00108	0.00564	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00108	0.00563	CbGpPWpGaD
Remifentanil—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.00107	0.0553	CbGeAlD
Remifentanil—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00107	0.00561	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00106	0.00552	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00104	0.00545	CbGpPWpGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00102	0.00531	CbGpPWpGaD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00102	0.00531	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00101	0.0053	CbGpPWpGaD
Remifentanil—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00101	0.0053	CbGpPWpGaD
Remifentanil—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.001	0.00523	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000989	0.00517	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000987	0.00516	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000977	0.00511	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000948	0.00495	CbGpPWpGaD
Remifentanil—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00094	0.00492	CbGpPWpGaD
Remifentanil—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000939	0.00491	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000919	0.0048	CbGpPWpGaD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000919	0.0048	CbGpPWpGaD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000914	0.00478	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000911	0.00476	CbGpPWpGaD
Remifentanil—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000893	0.00114	CcSEcCtD
Remifentanil—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000893	0.00467	CbGpPWpGaD
Remifentanil—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000893	0.00114	CcSEcCtD
Remifentanil—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000889	0.00113	CcSEcCtD
Remifentanil—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000888	0.00113	CcSEcCtD
Remifentanil—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000886	0.00113	CcSEcCtD
Remifentanil—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000886	0.00113	CcSEcCtD
Remifentanil—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000883	0.00113	CcSEcCtD
Remifentanil—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000879	0.0046	CbGpPWpGaD
Remifentanil—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000877	0.00112	CcSEcCtD
Remifentanil—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000877	0.00112	CcSEcCtD
Remifentanil—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000875	0.00112	CcSEcCtD
Remifentanil—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000872	0.00111	CcSEcCtD
Remifentanil—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000871	0.00111	CcSEcCtD
Remifentanil—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000871	0.00111	CcSEcCtD
Remifentanil—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000861	0.0011	CcSEcCtD
Remifentanil—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00086	0.0011	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00086	0.0011	CcSEcCtD
Remifentanil—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000858	0.00109	CcSEcCtD
Remifentanil—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000857	0.00109	CcSEcCtD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000857	0.00448	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000856	0.00448	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000856	0.00448	CbGpPWpGaD
Remifentanil—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000856	0.00109	CcSEcCtD
Remifentanil—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000854	0.00109	CcSEcCtD
Remifentanil—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000854	0.00109	CcSEcCtD
Remifentanil—OPRM1—brain—acquired immunodeficiency syndrome	0.000853	0.0439	CbGeAlD
Remifentanil—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000852	0.00109	CcSEcCtD
Remifentanil—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000852	0.00109	CcSEcCtD
Remifentanil—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000851	0.00109	CcSEcCtD
Remifentanil—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00085	0.00108	CcSEcCtD
Remifentanil—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000847	0.00108	CcSEcCtD
Remifentanil—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000846	0.00108	CcSEcCtD
Remifentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000845	0.00442	CbGpPWpGaD
Remifentanil—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000844	0.00108	CcSEcCtD
Remifentanil—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000844	0.00108	CcSEcCtD
Remifentanil—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000844	0.00108	CcSEcCtD
Remifentanil—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00084	0.00107	CcSEcCtD
Remifentanil—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000839	0.00107	CcSEcCtD
Remifentanil—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000839	0.00107	CcSEcCtD
Remifentanil—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000837	0.00107	CcSEcCtD
Remifentanil—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000836	0.00437	CbGpPWpGaD
Remifentanil—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000834	0.00106	CcSEcCtD
Remifentanil—Rash—Didanosine—acquired immunodeficiency syndrome	0.000832	0.00106	CcSEcCtD
Remifentanil—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000832	0.00106	CcSEcCtD
Remifentanil—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000832	0.00106	CcSEcCtD
Remifentanil—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000832	0.00106	CcSEcCtD
Remifentanil—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000828	0.00106	CcSEcCtD
Remifentanil—Headache—Didanosine—acquired immunodeficiency syndrome	0.000827	0.00105	CcSEcCtD
Remifentanil—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000826	0.00105	CcSEcCtD
Remifentanil—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000824	0.00105	CcSEcCtD
Remifentanil—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000824	0.00105	CcSEcCtD
Remifentanil—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000823	0.0043	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000823	0.0043	CbGpPWpGaD
Remifentanil—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000822	0.00105	CcSEcCtD
Remifentanil—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000821	0.00105	CcSEcCtD
Remifentanil—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.00082	0.00105	CcSEcCtD
Remifentanil—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000819	0.00104	CcSEcCtD
Remifentanil—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000819	0.00104	CcSEcCtD
Remifentanil—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000817	0.00104	CcSEcCtD
Remifentanil—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000816	0.00104	CcSEcCtD
Remifentanil—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000815	0.00104	CcSEcCtD
Remifentanil—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000813	0.00104	CcSEcCtD
Remifentanil—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000813	0.00104	CcSEcCtD
Remifentanil—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000812	0.00104	CcSEcCtD
Remifentanil—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000811	0.00103	CcSEcCtD
Remifentanil—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00081	0.00103	CcSEcCtD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000806	0.00421	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000806	0.00421	CbGpPWpGaD
Remifentanil—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000805	0.00103	CcSEcCtD
Remifentanil—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000805	0.00103	CcSEcCtD
Remifentanil—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000803	0.00102	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000802	0.00102	CcSEcCtD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000801	0.00419	CbGpPWpGaD
Remifentanil—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.0008	0.00102	CcSEcCtD
Remifentanil—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000799	0.00102	CcSEcCtD
Remifentanil—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000797	0.00102	CcSEcCtD
Remifentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000795	0.00415	CbGpPWpGaD
Remifentanil—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000794	0.00415	CbGpPWpGaD
Remifentanil—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000792	0.00101	CcSEcCtD
Remifentanil—Pain—Indinavir—acquired immunodeficiency syndrome	0.000792	0.00101	CcSEcCtD
Remifentanil—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000792	0.00414	CbGpPWpGaD
Remifentanil—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000791	0.00101	CcSEcCtD
Remifentanil—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000791	0.00101	CcSEcCtD
Remifentanil—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00079	0.00101	CcSEcCtD
Remifentanil—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000789	0.00101	CcSEcCtD
Remifentanil—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000787	0.001	CcSEcCtD
Remifentanil—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000787	0.001	CcSEcCtD
Remifentanil—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000786	0.001	CcSEcCtD
Remifentanil—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000784	0.001	CcSEcCtD
Remifentanil—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000784	0.001	CcSEcCtD
Remifentanil—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000783	0.000998	CcSEcCtD
Remifentanil—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000781	0.000996	CcSEcCtD
Remifentanil—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000781	0.000996	CcSEcCtD
Remifentanil—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00078	0.000995	CcSEcCtD
Remifentanil—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000778	0.000992	CcSEcCtD
Remifentanil—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000775	0.000988	CcSEcCtD
Remifentanil—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000774	0.000988	CcSEcCtD
Remifentanil—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000772	0.000985	CcSEcCtD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000772	0.00404	CbGpPWpGaD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000772	0.000985	CcSEcCtD
Remifentanil—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000771	0.00403	CbGpPWpGaD
Remifentanil—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00077	0.000983	CcSEcCtD
Remifentanil—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000766	0.000977	CcSEcCtD
Remifentanil—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000763	0.000974	CcSEcCtD
Remifentanil—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000762	0.000972	CcSEcCtD
Remifentanil—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00076	0.00097	CcSEcCtD
Remifentanil—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00076	0.00097	CcSEcCtD
Remifentanil—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00076	0.000969	CcSEcCtD
Remifentanil—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000759	0.000969	CcSEcCtD
Remifentanil—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000758	0.000967	CcSEcCtD
Remifentanil—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000758	0.000966	CcSEcCtD
Remifentanil—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000756	0.000964	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000756	0.000964	CcSEcCtD
Remifentanil—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000755	0.000963	CcSEcCtD
Remifentanil—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000755	0.000962	CcSEcCtD
Remifentanil—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000752	0.000959	CcSEcCtD
Remifentanil—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000752	0.000959	CcSEcCtD
Remifentanil—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000752	0.000958	CcSEcCtD
Remifentanil—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000749	0.000955	CcSEcCtD
Remifentanil—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000748	0.000955	CcSEcCtD
Remifentanil—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000748	0.000955	CcSEcCtD
Remifentanil—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000748	0.000954	CcSEcCtD
Remifentanil—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000748	0.000954	CcSEcCtD
Remifentanil—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000747	0.000952	CcSEcCtD
Remifentanil—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000747	0.000952	CcSEcCtD
Remifentanil—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000745	0.000951	CcSEcCtD
Remifentanil—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000745	0.000949	CcSEcCtD
Remifentanil—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000744	0.00389	CbGpPWpGaD
Remifentanil—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000744	0.000948	CcSEcCtD
Remifentanil—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000739	0.000943	CcSEcCtD
Remifentanil—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000737	0.00094	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000737	0.000939	CcSEcCtD
Remifentanil—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000736	0.000939	CcSEcCtD
Remifentanil—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000735	0.00384	CbGpPWpGaD
Remifentanil—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000733	0.000935	CcSEcCtD
Remifentanil—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000732	0.000934	CcSEcCtD
Remifentanil—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000731	0.000932	CcSEcCtD
Remifentanil—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000731	0.000932	CcSEcCtD
Remifentanil—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.00073	0.000931	CcSEcCtD
Remifentanil—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000729	0.000929	CcSEcCtD
Remifentanil—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000725	0.000925	CcSEcCtD
Remifentanil—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000725	0.000924	CcSEcCtD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000724	0.00379	CbGpPWpGaD
Remifentanil—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000724	0.000923	CcSEcCtD
Remifentanil—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000724	0.000923	CcSEcCtD
Remifentanil—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000724	0.000923	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000723	0.000922	CcSEcCtD
Remifentanil—Rash—Stavudine—acquired immunodeficiency syndrome	0.000723	0.000922	CcSEcCtD
Remifentanil—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000722	0.000921	CcSEcCtD
Remifentanil—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000722	0.00377	CbGpPWpGaD
Remifentanil—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000721	0.00092	CcSEcCtD
Remifentanil—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000721	0.000919	CcSEcCtD
Remifentanil—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00072	0.000918	CcSEcCtD
Remifentanil—Headache—Stavudine—acquired immunodeficiency syndrome	0.000718	0.000916	CcSEcCtD
Remifentanil—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000718	0.000915	CcSEcCtD
Remifentanil—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000717	0.000914	CcSEcCtD
Remifentanil—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000716	0.000913	CcSEcCtD
Remifentanil—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000716	0.000913	CcSEcCtD
Remifentanil—Rash—Abacavir—acquired immunodeficiency syndrome	0.000712	0.000908	CcSEcCtD
Remifentanil—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000711	0.000907	CcSEcCtD
Remifentanil—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000711	0.000907	CcSEcCtD
Remifentanil—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000711	0.000907	CcSEcCtD
Remifentanil—Headache—Abacavir—acquired immunodeficiency syndrome	0.000707	0.000902	CcSEcCtD
Remifentanil—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000705	0.000899	CcSEcCtD
Remifentanil—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000705	0.000899	CcSEcCtD
Remifentanil—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.0007	0.00366	CbGpPWpGaD
Remifentanil—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.0007	0.00366	CbGpPWpGaD
Remifentanil—Shock—Lamivudine—acquired immunodeficiency syndrome	0.0007	0.000892	CcSEcCtD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000699	0.00365	CbGpPWpGaD
Remifentanil—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000697	0.000889	CcSEcCtD
Remifentanil—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000697	0.000888	CcSEcCtD
Remifentanil—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000696	0.000888	CcSEcCtD
Remifentanil—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000696	0.00364	CbGpPWpGaD
Remifentanil—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000695	0.000887	CcSEcCtD
Remifentanil—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000695	0.000887	CcSEcCtD
Remifentanil—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000695	0.00363	CbGpPWpGaD
Remifentanil—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000692	0.000882	CcSEcCtD
Remifentanil—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000691	0.000881	CcSEcCtD
Remifentanil—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00069	0.00088	CcSEcCtD
Remifentanil—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00069	0.00088	CcSEcCtD
Remifentanil—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000688	0.000878	CcSEcCtD
Remifentanil—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000687	0.000877	CcSEcCtD
Remifentanil—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000684	0.00357	CbGpPWpGaD
Remifentanil—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000683	0.000871	CcSEcCtD
Remifentanil—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000683	0.00087	CcSEcCtD
Remifentanil—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000682	0.000869	CcSEcCtD
Remifentanil—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000682	0.000869	CcSEcCtD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000681	0.00356	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000681	0.00356	CbGpPWpGaD
Remifentanil—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000681	0.000868	CcSEcCtD
Remifentanil—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000671	0.000855	CcSEcCtD
Remifentanil—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000669	0.000854	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000669	0.000853	CcSEcCtD
Remifentanil—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000666	0.00348	CbGpPWpGaD
Remifentanil—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000665	0.000848	CcSEcCtD
Remifentanil—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000665	0.000847	CcSEcCtD
Remifentanil—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000664	0.000847	CcSEcCtD
Remifentanil—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000663	0.000845	CcSEcCtD
Remifentanil—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000662	0.000845	CcSEcCtD
Remifentanil—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000662	0.000845	CcSEcCtD
Remifentanil—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000662	0.000844	CcSEcCtD
Remifentanil—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000659	0.00084	CcSEcCtD
Remifentanil—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000656	0.000837	CcSEcCtD
Remifentanil—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000655	0.000836	CcSEcCtD
Remifentanil—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000653	0.00341	CbGpPWpGaD
Remifentanil—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000652	0.00341	CbGpPWpGaD
Remifentanil—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000645	0.000822	CcSEcCtD
Remifentanil—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000645	0.00337	CbGpPWpGaD
Remifentanil—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000644	0.000821	CcSEcCtD
Remifentanil—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000639	0.000814	CcSEcCtD
Remifentanil—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000638	0.000814	CcSEcCtD
Remifentanil—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000637	0.000813	CcSEcCtD
Remifentanil—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000637	0.000813	CcSEcCtD
Remifentanil—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000634	0.000808	CcSEcCtD
Remifentanil—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000634	0.000808	CcSEcCtD
Remifentanil—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000633	0.000808	CcSEcCtD
Remifentanil—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000632	0.000806	CcSEcCtD
Remifentanil—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00063	0.00329	CbGpPWpGaD
Remifentanil—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000628	0.000801	CcSEcCtD
Remifentanil—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000627	0.0008	CcSEcCtD
Remifentanil—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000626	0.000798	CcSEcCtD
Remifentanil—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000624	0.000796	CcSEcCtD
Remifentanil—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000619	0.00079	CcSEcCtD
Remifentanil—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000618	0.00323	CbGpPWpGaD
Remifentanil—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000617	0.000787	CcSEcCtD
Remifentanil—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000615	0.000785	CcSEcCtD
Remifentanil—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000614	0.000783	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000614	0.000783	CcSEcCtD
Remifentanil—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000614	0.00321	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000614	0.00321	CbGpPWpGaD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000613	0.0032	CbGpPWpGaD
Remifentanil—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000613	0.000781	CcSEcCtD
Remifentanil—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000612	0.000781	CcSEcCtD
Remifentanil—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00061	0.00319	CbGpPWpGaD
Remifentanil—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000608	0.000775	CcSEcCtD
Remifentanil—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000608	0.000775	CcSEcCtD
Remifentanil—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000599	0.00313	CbGpPWpGaD
Remifentanil—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000599	0.000764	CcSEcCtD
Remifentanil—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000593	0.000756	CcSEcCtD
Remifentanil—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000592	0.000755	CcSEcCtD
Remifentanil—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000592	0.000755	CcSEcCtD
Remifentanil—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000589	0.000751	CcSEcCtD
Remifentanil—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000589	0.000751	CcSEcCtD
Remifentanil—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000587	0.00307	CbGpPWpGaD
Remifentanil—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000586	0.000747	CcSEcCtD
Remifentanil—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000584	0.00305	CbGpPWpGaD
Remifentanil—Rash—Indinavir—acquired immunodeficiency syndrome	0.000584	0.000745	CcSEcCtD
Remifentanil—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000584	0.000744	CcSEcCtD
Remifentanil—Headache—Indinavir—acquired immunodeficiency syndrome	0.00058	0.00074	CcSEcCtD
Remifentanil—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000579	0.000738	CcSEcCtD
Remifentanil—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000573	0.000731	CcSEcCtD
Remifentanil—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000571	0.000728	CcSEcCtD
Remifentanil—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000565	0.00072	CcSEcCtD
Remifentanil—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000562	0.000717	CcSEcCtD
Remifentanil—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000557	0.00071	CcSEcCtD
Remifentanil—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000554	0.000706	CcSEcCtD
Remifentanil—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000552	0.00289	CbGpPWpGaD
Remifentanil—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000552	0.000704	CcSEcCtD
Remifentanil—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000552	0.00288	CbGpPWpGaD
Remifentanil—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000551	0.000703	CcSEcCtD
Remifentanil—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00055	0.000702	CcSEcCtD
Remifentanil—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000549	0.0007	CcSEcCtD
Remifentanil—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000548	0.000699	CcSEcCtD
Remifentanil—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000548	0.000699	CcSEcCtD
Remifentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000545	0.00285	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000542	0.00283	CbGpPWpGaD
Remifentanil—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000532	0.000679	CcSEcCtD
Remifentanil—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000532	0.00278	CbGpPWpGaD
Remifentanil—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00053	0.000676	CcSEcCtD
Remifentanil—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000528	0.000673	CcSEcCtD
Remifentanil—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000528	0.000673	CcSEcCtD
Remifentanil—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000527	0.000673	CcSEcCtD
Remifentanil—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000525	0.000669	CcSEcCtD
Remifentanil—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000524	0.000668	CcSEcCtD
Remifentanil—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00052	0.000663	CcSEcCtD
Remifentanil—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000519	0.00271	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000519	0.00271	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000518	0.00271	CbGpPWpGaD
Remifentanil—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000512	0.000653	CcSEcCtD
Remifentanil—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00051	0.00065	CcSEcCtD
Remifentanil—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000507	0.00265	CbGpPWpGaD
Remifentanil—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000503	0.000642	CcSEcCtD
Remifentanil—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000497	0.000634	CcSEcCtD
Remifentanil—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000494	0.00258	CbGpPWpGaD
Remifentanil—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000493	0.000629	CcSEcCtD
Remifentanil—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000492	0.000628	CcSEcCtD
Remifentanil—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000488	0.000623	CcSEcCtD
Remifentanil—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000488	0.000622	CcSEcCtD
Remifentanil—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000487	0.00062	CcSEcCtD
Remifentanil—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000485	0.000619	CcSEcCtD
Remifentanil—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00048	0.00251	CbGpPWpGaD
Remifentanil—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000474	0.000604	CcSEcCtD
Remifentanil—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00047	0.0006	CcSEcCtD
Remifentanil—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00047	0.000599	CcSEcCtD
Remifentanil—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00047	0.000599	CcSEcCtD
Remifentanil—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000467	0.000595	CcSEcCtD
Remifentanil—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000467	0.00244	CbGpPWpGaD
Remifentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000467	0.00244	CbGpPWpGaD
Remifentanil—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00046	0.000587	CcSEcCtD
Remifentanil—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000458	0.00239	CbGpPWpGaD
Remifentanil—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000452	0.000577	CcSEcCtD
Remifentanil—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000448	0.000572	CcSEcCtD
Remifentanil—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000448	0.000571	CcSEcCtD
Remifentanil—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000445	0.000568	CcSEcCtD
Remifentanil—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.000565	CcSEcCtD
Remifentanil—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.00043	0.00225	CbGpPWpGaD
Remifentanil—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000422	0.000539	CcSEcCtD
Remifentanil—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000422	0.00221	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000421	0.0022	CbGpPWpGaD
Remifentanil—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000421	0.0022	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000404	0.00211	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000404	0.00211	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000395	0.00207	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000395	0.00207	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000394	0.00206	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000382	0.002	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00037	0.00194	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000369	0.00193	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000365	0.00191	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000359	0.00188	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000359	0.00188	CbGpPWpGaD
Remifentanil—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000355	0.00186	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000354	0.00185	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000354	0.00185	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000347	0.00181	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000347	0.00181	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000335	0.00175	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00032	0.00167	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000315	0.00165	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000315	0.00165	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000313	0.00164	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000312	0.00163	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000301	0.00157	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000299	0.00156	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000299	0.00156	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000296	0.00155	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000293	0.00153	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000293	0.00153	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000283	0.00148	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000273	0.00143	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000271	0.00142	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000271	0.00141	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000269	0.00141	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000266	0.00139	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000266	0.00139	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000264	0.00138	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00026	0.00136	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000249	0.0013	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000246	0.00129	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00024	0.00125	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000238	0.00124	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000236	0.00123	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000226	0.00118	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000223	0.00117	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00022	0.00115	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000219	0.00114	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000216	0.00113	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000212	0.00111	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000212	0.00111	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000202	0.00106	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000201	0.00105	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000199	0.00104	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000198	0.00103	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000186	0.000972	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000186	0.000972	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000185	0.000966	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000182	0.000953	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000167	0.000874	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000161	0.000843	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000159	0.000831	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000157	0.000822	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000157	0.000822	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000157	0.000818	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000145	0.00076	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000142	0.000743	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000142	0.00074	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000139	0.000728	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000137	0.000718	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000127	0.000666	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000125	0.000652	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00012	0.000625	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000118	0.000616	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000116	0.000607	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000108	0.000563	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000105	0.000551	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.4e-05	0.000439	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.36e-05	0.000437	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.37e-05	0.000385	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.33e-05	0.000383	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.23e-05	0.000325	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.19e-05	0.000324	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.94e-05	0.000258	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.33e-05	0.000226	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.66e-05	0.000191	CbGpPWpGaD
